Anti-Rheumatic Rx
Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features. Non-invasive imaging is key in detecting large vessel involvement in GCA, as many of these patients do not experience signs or symptoms specific to this vascular disease (i.e.
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!
Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.
Dr. John Cush RheumNow
1 month 1 week ago
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE
Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE
https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf
Dr. John Cush RheumNow
1 month 1 week ago
Day 1 Recap: #ACR25 Highlights
Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1 highlights from the 2025 ACR Convergence in Chicago, focusing on abstracts/sessions: 0775, SLE guidelines, 0163, 0832, 0776, 0792, and 0164. https://t.co/ODte4XY82a
Nouf Al hemmadi NoufAhmedAlham2
1 month 1 week ago
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x
Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD .
I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring.
@RheumNow
#ACR25
sheila RHEUMarampa
1 month 1 week ago
Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC
TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN.
AE rates comparable.
TAC - AKI & tremor
MMF - leucopenia
reassuring data.more tx options.
#ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL
Akhil Sood MD, MS AkhilSoodMD
1 month 1 week ago
LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN:
🔹100% discontinued biologics & IS at follow-up
🔹Renal response ~78%
🔹CRS mostly Grade 1–2 (~70%); ≥Grade 3 AEs = transient & hematologic
@RheumNow #ACR25 https://t.co/oNK4wtLGYV
Akhil Sood MD, MS AkhilSoodMD
1 month 1 week ago
Another toxicity signal to watch in the CAR T space: LICATs
Abstract 1537 reports a new immune-related toxicity distinct from CRS or ICANS:
🔹Affects organs prev involved in autoimmune dx: skin (35%) and kidneys (22%)
🔹Mostly mild (Grade 1–2); 3 cases Grade 3
@RheumNow #ACR25 https://t.co/mtZh47nWtv
Janet Pope Janetbirdope
1 month 1 week ago
#SLE #DORIS #remission is RARE and without #prednisone even rarer
#ASIA #Pacific 5K pts over 10 yrs
A call to do better
82% LLDAS, 70% remission, 31% GC-free remission (REM-0) at least once
abst#595 @ACRheum @RheumNow
#ACRBest https://t.co/OK6sYnqs81
Poster Hall